GILL QUARTERLY PUBLISHED BY UK GILL HEART & VASCULAR INSTITUTE - Summer 2021 - University of Kentucky
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
GILL QUARTERLY PUBLISHED BY UK GILL HEART & VASCULAR INSTITUTE Summer 2021
GILL QUARTERLY SUMMER 2021 TABLE OF CONTENTS Clinical Trials | Page 3 Fellows News/Accomplishments | Page 6 Affiliate News | Page 12 Features | Page 14 CV-RPA | Page 24 Current Research Funding | Page 26 Publications | Page 31
3 | Gill Quarterly, Winter 2020
FEATURED Trial). REVERSE-IT is a multi-center, open-label,
prospective single-arm trial designed to study rever-
CLINICAL TRIAL sal of the antiplatelet effects of ticagrelor with ben-
tracimab in patients who present with uncontrolled
REVERSE-IT: A Phase 3, Multicenter, major or life-threatening bleeding or who require
Open-Label, Single-Arm Study of PB2452 in urgent surgery or invasive procedure. Approximately
Ticagrelor-Treated Patients with Uncontrolled 200 patients are being targeted to be enrolled from
Major or Life-Threatening Bleeding or Requir- major health centers worldwide. Patients with re-
ing Urgent Surgery or Invasive Procedure ported use of ticagrelor within the prior 3 days who
require urgent reversal due to uncontrolled major or
PI: Ahmed Abdel-Latif, MD, PhD life-threatening bleeding or because they need ticagre-
Sponsor: PhaseBio Pharmaceuticals Inc lor reversal will be eligible for enrollment.
Objective: To demonstrate reversal of the antiplate- As of March 2021, the REVERSE-IT Phase 3 clinical
let effects of ticagrelor with IV infusion of PB2452 and trial had enrolled 60 of the first approximately 100
to demonstrate the clinical efficacy of PB2452 by as- patients needed to support a Biologics License Appli-
sessment of hemostasis in ticagrelor-treated patients cation (BLA), nearly all of whom to date have required
with uncontrolled major or life-threatening bleeding urgent surgery or an invasive procedure. PhaseBio is
or who are undergoing urgent surgery or invasive pro- attempting to accelerate enrollment of patients with
cedure in a an open-label, single-cohort study.months, uncontrolled major or life-threatening bleeding, in-
or an elevation in a certain blood test for HF, called cluding by working to increase the number of enroll-
BNP or NT-pro-BNP. ing clinical trial sites in the United States, Canada, and
the European Union as it is believed that a broader
For More information contact: Stephanie Mor- site footprint will increase the probability of enrolling
ris: stephanie.a.morris@uky.edu these patients. The trial is enrolling faster than Phase-
Phone: 859-323-5366 Bio originally projected, and PhaseBio now expects
to complete enrollment of the first 100 patients in
Trial Background: Bentracimab (previously mid-2021 and is targeting to submit a BLA for ben-
PB2452) has been studied in Phase 1 and Phase 2 tracimab in mid-2022, although those timelines could
clinical trials and has demonstrated the potential to be impacted by the continued scope and duration of
bring life-saving therapeutic benefit through immedi- the COVID-19 pandemic.
ate and sustained reversal of the antiplatelet activity of
ticagrelor, potentially mitigating concerns regarding
bleeding risks associated with the use of antiplatelet
drugs. Additionally, in a translational study, ben- For additional trial information, please visit:
tracimab achieved equivalent reversal of branded ClinicalTrials.gov
ticagrelor and multiple ticagrelor generics. The pivotal
Phase 3 clinical study is called REVERSE-IT (Rapid
and SustainEd ReVERSal of TicagrElor – Intervention
4 | UK Gill Heart & Vascular Institute
CURRENTLY ENROLLING
CLINICAL TRIALS
BIO LIBRA - AnaLysIs of Both Sex and Device persistent AF subtypes implanted with a two-lead
Specific FactoRs on Outcomes in PAtients with BIOTRONIK CRT-DX system.
Non-Ischemic Cardiomyopathy
LEADLESS-II - A safety and effectiveness trial
PI: Aaron Hesselson, MD for a leadless pacemaker system
Coordinator: Ben Rushing 859-323-5259
PI: Aaron Hesselson, MD
Objective: This study is designed to evaluate the com- Coordinator: Jennifer Isaacs 859-323-4738
bined risk of all-cause mortality and treated ventric-
ular tachycardia (VT) or ventricular fibrillation (VF) Objective: To confirm the safety and effectiveness of
events by subject sex and by implanted device type. the Aveir device from implant through 6-weeks in a
All-cause mortality, VT or VF alone, risk of cardiac subject population indicated for a VVI(R) pacemaker.
death, and sudden cardiac death will be analyzed for
the total cohort, as well as by subject sex and by the General Cardiology:
implanted device type
EMPACT-MI – A study to test whether em-
OPTIMIZER SMART POST - APPROVAL pagliflozin can lower the risk of heart failure
STUDY and death in people who had a heart attack
(myocardial infarction)
PI: Aaron Hesselson, MD
Coordinator: Ben Rushing 859-323-5259 PI: John Kotter, MD
Coordinator: Ben Rushing 859-323-5259
Objective: Post-approval study that evaluates data
such as cardiac outcomes, quality of life, mortality, Objective: To demonstrate the superiority of empagli-
and functionality. Long-term data needed to assess flozin 10 mg once daily versus placebo, in addition to
complication rates and potential interactions with oth- standard of care, for the reduction of the composite
er implantable devices in the intended patient popula- endpoint of time to first heart failure hospitalization
tion. The post-approval study (PAS) protocol designed or all-cause mortality in high-risk patients hospital-
to address these concerns in a real-world setting. ized for acute MI.
BIO-AffectDX- Atrial Fibrillation associated RELIEVE-HF TRIAL: REducing Lung con-
with Heart Failure treated by BIOTRONIK’s gestIon symptoms using the v-wavE shunt in
CRT-DX System adVancEd Heart Failure
PI: Aaron Hesselson, MD PI: John Gurley, MD
Coordinator: Ben Rushing 859-323-5259 Coordinator: Stephanie Morris 859-323-5366
Objective: To evaluate the percent of all subjects with Objective: To provide reasonable assurance of safety
improvement from baseline in heart failure patients and effectiveness of the V-Wave Interatrial Shunt Sys-
with paroxysmal, persistent, and long-standing tem by improving meaningful clinical outcomes in
5 | Gill Quarterly, Summer 2021
CLINICAL TRIALS CONTINUED
patients with NYHA functional class II, class III or Coordinator: Evan Cassity 859-218-6633
ambulatory class IV heart failure, irrespective of left
ventricular ejection fraction, who at baseline are treat- Objective: To determine whether intensive medi-
ed with guideline-directed drug and device therapies. cation treatment to modify risk factors and vascular
function in women patients with coronary arteries
REVERSE-IT: A Phase 3, Multicenter, showing no flow limit obstruction but with cardiac
Open-Label, Single-Arm Study of PB2452 in symptoms (i.e., chest pain, shortness of breath) will
Ticagrelor-Treated Patients with Uncontrolled reduce the patient’s likelihood of dying, having a heart
Major or Life-Threatening Bleeding or Requir- attack, stroke/TIA or being hospitalized for cardiac
ing Urgent Surgery or Invasive Procedure reasons.
PI: Ahmed Abdel- Latif, MD, PhD
Coordinator: Jennifer Isaacs 323-4738 Clinical Research Team
Brief Summary: John Kotter, MD
The study will demonstrate the reversal of the atiplate- Director, Gill Heart & Vascular Institute Cardiology
let effects of ticagrelor with IV infusion of PB2452 Research Center
and the clinical efficacy of PB2452 by assessment of
hemostasis in ticagrelor-treated patients with uncon- Jennifer Isaacs, MS, MS, CCRP
trolled major or life-threatening bleeding or who are Clinical Research Administrative Director
undergoing urgent surgery or invasive procedure in a Cardiovascular and Radiology Services
an open-label, single-cohort study. Gill Heart & Vascular Institute Clinical Research
859-323-4738
MK-5475-007: A Phase 2/3, Multicenter, Ran- Jennifer.isaacs@uky.edu
domized, Double-blind, Placebo-Controlled,
Adaptive Design Study to Evaluate the Efficacy Stephanie Morris, CCRP
and Safety of MK-5475 in Adults with Clinical Research Operations Manager
Pulmonary Arterial Hypertension Cardiovascular and Radiology Services
Gill Heart & Vascular Institute Clinical Research
PI: David Booth, MD Phone: 859-323-5366
Coordinator: Stephanie Morris 859-323-5366 Stephanie.A.Morris@uky.edu
Objective: Two cohorts to evaluate the effect of MK- Research Coordinators
5475: 1) versus placebo on the pulmonary vascular
resistance (PVR) at Week 12, 2) versus placebo on Ben Rushing, CCRC
6-minute walk distance (6MWD) at Week 12. 859-323-5259
Ben.rushing@uky.edu
Women’s Cardiology:
Travis Sexton, PhD
Women’s IschemiA TRial to Reduce Events In 859-323-1082
Non-ObstRuctive CAD (WARRIOR) trsext2@uky.edu
PI: Gretchen Wells, MD, PhD
6 | UK Gill Heart & Vascular Institute
FELLOWS NEWS/ACCOMPLISHMENTS
ACC.21 POSTERS & ABSTRACTS
8 | | UK Gill Heart & Vascular Institute
FELLOWS NEWS
ACC.21 ABSTRACTS
CORONARY ARTERY DIS- MANAGING TRICUSPID LONG TERM OUTCOMES
EASE PROGRESSION IN VALVE INFECTIVE ENDO- IN CARDIAC RHYTHM
PATIENTS WITH END-STAGE CARDITIS IN INTRAVENOUS MANAGEMENT DEVICE
LIVER DISEASE: FINDINGS DRUG USERS: IS IT TIME TO PLACEMENT FOLLOWING
FROM CCTA MAY IMPACT ENDORSE THE CONSERVA- INSIDE-OUT CENTRAL VE-
PREOPERATIVE CARDIAC TIVE APPROACH? NOUS ACCESS TECHNIQUE
TESTING RECOMMENDA-
TIONS Rvan Ruhr, Talal Alnabelsi, Grego- Ethan Fry, Gregory Sinner, Karam
ry Sinner, Steve Leung Ayoub, Aaron Hesselson
Zachary Neace, Caleb W. Phillips,
Gregory Sinner, Talal S. Alnabelsi,
Malay B. Shah, Roberto Gedaly, Ve- IMPLANTABLE CARDIO- DETERMINATION OF LEFT
dant Gupta, Vincent Sorrell, Steve VERTER DEFIBRILLATOR MAIN CORONARY ARTERY
Leung THERAPY IN PATIENTS STENOSIS VIA NON-INVA-
WITH END STAGE RENAL SIVE TESTING TO GUIDE
UNDERUTILIZATION OF STA- DISEASE RESULTS FROM REVASCULARIZATION IN
TIN THERAPY IN PATIENTS THE NATIONWIDE INPA- ISCHEMIC HEART DISEASE
WITH END-STAGE LIVER TIENT SAMPLE DATABASE
DISEASE AND CORONARY Thomas H. Wool, Vedant A. Gupta
ARTERY CALCIFICATION Karam Ayoub, Ethan Fry, Meera
Marji, Ahmad Masri, Aaron Hes-
Gregory J. Sinner, Do Hyun Yun, selson, Kristin Ellison
Mihir G. Shah, Vedant Gupta,
Malay B. Shah, Roberto Gedaly, THE SAFETY OF PULMO-
Vincent Sorrell, Steve Leung NARY VEIN ISOLATION
IN PATIENTS WITH ATRI-
WOMEN BENEFIT FROM CRT AL FIBRILLATION AND
GREATER THAN MEN, AND CHRONIC THROMBOCYTO-
IT IS DUE TO MORE THAN PENIA-RESULTS FROM THE
JUST VENTRICULAR SIZE NATIONWIDE INPATIENT
SAMPLE DATABASE
Josue Villegas-Galaviz, Mark
Kauth, Eric Robinson, Gregory Karam Ayoub, Ethan Fry, Meera
Sinner, Tanyanan Tanawuttiwat, Marji, Ahmad Masri, Kristin Elli-
Maya Guglin son, Aaron Hesselson
9 | Gill Quarterly, Spring 2021
FELLOWS NEWS
GRADUATION
Advanced Cardiac Imaging
Cardiovascular Disease
Ahmed Noor
Ashley Brunmeier
Joshua Duchesne Gregory Sinner
Joshua Eason
Mary-Beth Fisher Electrophysiology
Brian Kauh Karam Ayoub
Matthew Rafn
Matthew Sousa Interventional Cardiology
Luai Alhazmi
Advanced Heart Failure Hussam Hawmdeh
Jad Ballout
Muhammad Nadeem
Congratulations!
For more photos please use the link below:
https://markmahan.photoshelter.com/gallery/210606-
Gill-Heart/G00003XWJqbJPI9U/C0000C3hNi6d9fSQ
Password: UK
10 | | UK Gill Heart & Vascular Institute
FELLOWS NEWS
AWARDS
Michael G. Spain
Award
Given to faculty/staff for
extraordinary contribu-
tions toward the better-
ment of the fellowship
program–
Dr. David Booth
Borys Surawicz
Award
Given to a faculty mem-
ber for excellence in
teaching –
Dr. Vedant Gupta11 | Gill Quarterly, Summer 2021 David J. Moliterno Award for Excellence in Clinical Research – Drs Gregory Sinner and Karam Ayoub Teresa Hignite Award Given to a fellow who exhibits exceptional pro- fessionalism and a positive attitude – Dr. Ashley Brunmeier
12 | | UK Gill Heart & Vascular Institute
AFFILIATE NEWS
THE PULSE - NEXT WEBINAR
JULY 14
The Pulse is the Gill Affiliate This CME-accredited webinar For additional information about
Network’s official webinar series. will feature heart failure cardi- the webinar and to RSVP, please
Held bimonthly, these educa- ologist, Dr. Gaurang Vaidya, contact Rebecca Craft by phone
tional courses are accredited who will present, Cardiac at (859) 285-8083 or by email at
for multiple clinical personnel Amyloidosis: ATTR-acting All rebecca.craft@uky.edu.
and focused on a broad range of Our Attention. Dr. Vaidya’s
topics relating to cardiovascular presen-tation will focus on Join us for future The Pulse we-
clinical care, program manage- recognizing, diagnosing, and binars:
ment, and administration. treating cardiac amyloidosis.
Advanced Therapies for
The next, The Pulse webinar, To connect remotely, please use Heart Failure
is scheduled for Wednesday, the following link: https://uky. Emma Birks, MD
July 14 from 12:00 – 1:00 zoom.us/j/87434783148. September 29, 2021/12-1PM EST
PM EST.
Surgical Considerations in
Heart Transplantation
Mike Sekela, MD
November 10, 2021/7-8 AM EST2 | UK Gill Heart & Vascular Institute
Above from L to R: Drs. Sharat Koul, Aslam Ahmad, Gary Grigsby Jr., Shawn Flynn, and Hussam Hamdalla
EPHRIAM MCDOWELL REGIONAL MED CENTER
RECEIVES NEW ACCREDITATION
Congratulations to Gill Affiliate Ephraim McDowell Health. Ephraim McDowell Heart &
Network member, Ephraim Mc- “Our associates and physicians Vascular Institute is located
Dowell Regional Medical Center con-tinually work together to at 216 West Walnut Street in
(EMRMC)! pro-vide the best care possible Danville, across from Ephraim
for the patients we serve.” McDowell Regional Medical
The American College of Car- Center. EMRMC physicians also
diology has recently recognized Congratulations to Ephraim see patients at these other loca-
Ephraim McDowell for its McDowell on this recognition. tions in central Kentucky:
demonstrated expertise and Thank you for your continued
commitment in treating patients focus on excellent cardiovascu- Liberty – 511 Middleburg Street
with chest pain, and EMRMC lar care. We’re proud to have Harrodsburg – 470 Linden Ave-
has been awarded Chest Pain you in the Gill Affiliate family! nue, Suite 7
Center Accreditation with
Primary PCI based on rigorous To learn how the Gill Affiliate Springfield – 280 Lincoln Drive
onsite evaluation of the staff’s Network is working across the Russell Springs – 92 Dr. Joe T.
ability to evaluate, diagnose and Commonwealth to ensure ac- Pettey Drive, Suite 600
treat patients who may be expe- cess to high-quality care for all
Kentuckians, visit: Monticello – One South Creek
riencing a heart attack.
Drive, Suite 102
https://ukhealthcare.uky.edu/
“By earning Chest Pain Center
gill-heart-vascular-institute/
accreditation, it validates to our
professionals/affiliates
communities that we are dedi-
cated to providing excellent care
for our chest pain patients,” says
Dan McKay, president and CEO,14 | | UK Gill Heart & Vascular Institute
RESEARCH NEWS
NIGMS R35 GRANT
UK Professor Awarded $1.9M for Sepsis Research
A University of Kentucky College Li studies how hormones called given to patients without consid-
of Medicine professor has been glucocorticoids regulate the ering the status of adrenal insuf-
awarded a $1.9 million National body’s immune system in re- ficiency. Li proposes that before
Institutes of Health (NIH) grant sponse to sepsis. Glucocorti- giving glucocorticoids to septic
for his research on the body’s im- coids are released by the adrenal patients, a precision medicine
mune response to sepsis, which glands and help to reduce certain approach should be taken to
could potentially help to improve aspects of immune function such identify whether or not they have
therapies for the common dis- as inflammation. They are often an adrenal insufficiency.
ease. supplemented as a therapy to
treat sepsis and other diseases “The mechanisms behind gluco-
Xiangan Li, a professor in the caused by an overactive immune corticoids and immune regula-
Department of Physiology and system. However, not all sepsis tion may be different than previ-
the Saha Cardiovascular Re- patients may benefit from addi- ously understood,” Li said. “The
search Center, received the tional glucocorticoids, Li says. ongoing research funded by this
prestigious R35 grant from the grant will answer questions that
NIH’s National Institute of Gen- “Thirty to 60% of sepsis patients we hope will improve the overall
eral Medical Sciences (NIGMS), have an impaired adrenal stress efficacy of sepsis therapy and
which will fund sepsis research in response and cannot produce save many lives.”
his lab over the next five years. enough glucocorticoids,” said Li.
“But for the others, supplement-
Sepsis is a life-threatening ing glucocorticoids may not be Research in Li’s lab will continue
condition that occurs when an necessary or beneficial.” to give scientists a better under-
infection triggers a chain reaction standing of the role glucocorti-
throughout the body. Without Research conducted in Li’s lab coids play in immune function,
timely treatment, it can quick- provides a proof of concept that it which could ultimately lead to
ly lead to tissue damage, organ could actually be harmful. Septic improved patient outcomes for
failure and death. The Centers mice were treated with glucocor- sepsis.
for Disease Control and Preven- ticoids and those with impaired
tion reports that nearly 270,000 adrenal stress responses had “The mechanisms behind gluco-
Americans die as a result of sep- better outcomes, but those with corticoids and immune regula-
sis every year, and one in three normal adrenal stress responses tion may be different than previ-
patients who die in a hospital has experienced increased mortality ously understood,” Li said. “The
sepsis. as a result of the therapy. ongoing research funded by this
grant will answer questions that
Li says the findings provide an we hope will improve the overall
“Thirty to 60% of sepsis patients explanation for why the current efficacy of sepsis therapy and
have an impaired adrenal stress glucocorticoid therapy for sepsis save many lives.”
response and cannot produce is controversial, as the therapy is
enough glucocorticoids,” said Li.2 | UK Gill Heart & Vascular Institute
The NIGMS aims to support Story from UK COM web page: Recent publications:
basic research that increases the https://research.med.uky.edu/ Ito, M.; Wang, Q.; Hao, D.;
understanding of biological pro- news/uk-professor-award- Sawada, H.; Huang, B.; Guo, L.;
cesses and lays the foundation ed-19m-sepsis-research Daugherty, A.; Li, XA “Ultrasound
for advances in disease diagno- Monitoring of Thymus Involution
in Septic Mice.” Ultrasound in
ses and prevention. The NIGMS’
medicine & biology 47, 3 (2021):
R35 grant, also called the Max- Lab Information 769-776. [PubMed Link]
imizing Investigators Research
Award (MIRA), increases the Li Lab Members: Ito, M.; Ye, X.; Wang, Q.; Guo, L.;
efficiency of NIGMS funding Ling Guo, MD Hao, D.; Howatt, D.; Daugherty,
by providing researchers with Qian Wang, BS A.; Cai, L.; Temel, R.; Li, XA “SR-
greater stability and flexibility, Dan Hao, MS BI (Scavenger Receptor BI), Not
thereby enhancing scientific Misa Ito, MD LDL (Low-Density Lipoprotein)
productivity and the chances for Receptor, Mediates Adrenal Stress
Dr. Li’s Website click here. Response-Brief Report.” Arterio-
important breakthroughs.
sclerosis, thrombosis, and vascular
biology 40, 8 (2020): 1830-1837.
Research reported in this pub- [PubMed Link]
lication was supported by the
National Institute of General Wu C, Lu W, Zhang Y, Zhang G, Shi
Medical Sciences of the Nation- X, Hisada Y, Grover SP, Zhang X,
al Institutes of Health under Li L, Xiang B, Shi J, Li XA, Daugh-
Award Number R35GM141478. erty A, Smyth SS, Kirchhofer D,
The content is solely the re- Shiroishi T, Shao F, Mackman N,
sponsibility of the authors and Wei Y, Li Z. Inflammasome Acti-
vation Triggers Blood Clotting and
does not necessarily represent
Host Death through Pyroptosis.
the official views of the National Immunity. 2019 Jun18;50(6):1401-
Institutes of Health. 1411.e4. [PubMedLink]16 | | UK Gill Heart & Vascular Institute
RESEARCH NEWS
MYOCARDIAL RECOVERY ALLIANCE
MYRA: An Alliance Finding Innovative Approaches for Improved Cardiac Recovery
For many years, ventricular Emma Birks, MD, PhD, and Ken tucky, having come from “one
assist devices (VADs) were con- Campbell, PhD, are co-principal U.K. to another.”
sidered a last resort for patients investigators of the Myocardial
with serious heart failure. These Recovery Alliance (MYRA), a Dr. Birks is from England, where
mechanical pumps, which help team established under the UK she earned her training and
maintain blood circulation, were College of Medicine’s Alliance became a global leader in myo-
mainly used for patients awaiting Research cardial recovery and the study
a heart transplant. Initiative. Together, with a team of VADs. She has led numerous
of highly qualified cardiovascu- clinical trials and long studied
Recent studies conducted by lar experts and scientists across molecular mechanisms impacting
University of Kentucky research- campus, they’re leading revolu- heart failure and recovery. She
ers suggest VADs actually could tionary studies that could change recently joined the University
be used to recover the hearts standards of cardiac care in real of Kentucky as section chief of
of patients with heart failure, time. advanced heart failure, mechani-
even those with advanced heart cal circulatory support, and heart
failure, possibly preventing Cardiovascular disease is one of transplantation after nearly a
their need for transplants in the the Research Priority Areas from decade at the University of Lou-
future. the UK Office of the Vice Presi- isville.
dent for Research.
Holding this research at UK Dr. Birks and Dr. Campbell bring
could be groundbreaking for the “In the early days, no one really international experience to Ken-
state of Kentucky. UK Health- wanted to be involved with VADs tucky, having come from “one
Care performs more than 40 because the outcomes weren’t U.K. to another.”
heart transplants per year, or good,” Dr. Birks said. “But we
one percent of heart transplants found that by changing the pa- Dr. Campbell, originally from
worldwide. rameters on the pump, we can get Scotland, is a professor of phys-
patients to feel better. When you iology with expertise in cardiac
take a very sick young person and contractility and mathematical
“In the early days, no one really you get them to survive and live modeling of cell and molecu-
wanted to be involved with VADs with the pump, then go home and lar-level contractile function. He
because the outcomes weren’t have a good quality of life and joined the University of Kentucky
good,” Dr. Birks said. “But we then ultimately return the heart in 1998 and now directs the Cen-
found that by changing the pa- function to normal, it’s really very ter for Clinical and Translational
rameters on the pump, we can rewarding.” Science (CCTS) Biospecimens
get patients to feel better”. Core.
Dr. Birks and Dr. Campbell bring
international experience to Ken2 | UK Gill Heart & Vascular Institute
The collaborative structure of Meanwhile, the team benefits beyond to better understand
the Alliance Research Initiative greatly from Dr. Campbell’s myocardial recovery while
has played a major role in bridg- leadership of the CCTS Biospec- allowing patients with serious
ing the connections between imens Core and the Gill Cardio- heart failure to live longer,
researchers and cardiologists, vascular Biorepository. These healthier lives.
which is not a simple task but biobanks provide researchers
one that can make a huge differ- and clinicians within MYRA To learn more about MYRA and
ence in accelerating the research samples of myocardium donat- our other Alliance teams, click
process. Due to the nature of ed by patients for research. here: https://med.uky.edu/al-
the profession, clinicians invest liance.
much of their time in practice. In Collaborations across depart-
the MYRA Alliance Dr. Birks and ments and colleges have al- MYRA TEAM MEMBERS:
other cardiologists are invested lowed the MYRA team to make Ahmed Abdel-Latif, MD, PhD
in research, too. strides in research and clinical Mark Ebbert, PhD
developments. The team al- Vedant Gupta, MD
“Before joining MYRA, I might ready has developed computer
Candice Harvey Falls, PhD
not have been able to connect models of hearts that evolve
so easily with specialists in- in response to pharmaceutical Andrew Kolodziej, MD
volved in clinical care, but now and genetic manipulation at the Sarah Kosta, PhD
I have nearly 15 cardiologists in molecular level. Clinicians and John Kotter, MD
my phone contacts who I can scientists will use knowledge
Steve Leung, MD
reach out to, and sometimes get gained from these models to
responses in 30 seconds,” Dr. improve patient care and treat- Bryana Levitan, RDCS
Campbell said. “These connec- ment. Greg Milburn, MD/PhD Student
tions aren’t unheard of, but Vince Sorrell, MD
rare, and they are really crucial With the right connections to William Stoops, PhD
in making our research more experts and resources, MYRA
efficient.” Gaurang Vaidya, MD
is poised to lead clinicians and
researchers in Kentucky and Jonathan Wenk, PhD18 | UK Gill Heart & Vascular Institute
APRIL
SAHA AORTIC CENTER
A new research center focused on aortic disease “Dr. Saha has devoted a lifetime of service to
has been established at the University of Kentucky the health care needs of Kentucky. The gen-
thanks to a gift from the Saha Foundation. erous gift attests to his and his family’s pas-
sion and dedication to our Commonwealth,”
Housed in the Biomedical Biological Science Re- Minion said. “I am honored to be a part of this
search Building on the UK campus, the Saha Aortic exciting initiative.”
Center will promote research and education to Sheppard founded the UK Aortic Clinic and
advance clinical care for disease of the aorta. Aortic performs NIH-funded research on Marfan
disease can cause the expansion and rupture of a syndrome and genetically based aortic disease.
vessel wall in the chest or abdominal area, leading She works closely with vascular surgeons to
to potentially deadly internal bleeding. provide a transdisciplinary team approach for
managing patient’s aortic disease.
Alan Daugherty, Ph.D., chair of the Department of
Physiology and director of the Saha Cardiovascular “This donation from the Saha Foundation is a
Research Center in the UK College of Medicine, tremendous gift to the people of Kentucky, as
will serve as director of the Saha Aortic Center. they will not need to leave the state to access
the most cutting-edge care for aortic disease,”
“Aortic disease affects the major artery that car- Sheppard said. “We have one of the largest
ries blood from the heart to the rest of the body,” groups of basic scientists in the world who
Daugherty said. “Having this center that specifical- do research on aortic disease. By facilitating
ly focuses on research and education in this field is collaboration with our physicians, this gift
vital.” will position UK to be a premier center for
the treatment of people with aortic disease
David Minion, MD, program director and pro- throughout the world.”
fessor of Vascular Surgery, and Mary Sheppard,
MD, assistant professor of Family and Community The Saha Foundation was established in 1999
Medicine, Surgery and Physiology, will serve as by Dr. Sibu and Becky Saha. Its mission is to
co-directors for the center. promote research and education of cardiovas-
cular disease in the Commonwealth of Ken-
tucky. The foundation offers many awards and
scholarships to scientists, medical students,
nurses and other health professionals.
“This donation from the Saha Foundation is a tre-
mendous gift to the people of Kentucky, as they will The Saha’s have considered Lexington home
not need to leave the state to access the most cut- for more than 40 years and remain steadfast
ting-edge care for aortic disease,” Sheppard said. in their community involvement and generous
philanthropy. Following a distinguished career
in private practice, Dr. Saha joined the faculty
of the UK College of Medicine in 2002 as aprofessor of surgery in the Division of Cardio-
thoracic Surgery. Becky is past president of VACE Poster Pitch Winner!
Friends of the Arboretum. During her ten-
ure as president, Friends of the Arboretum
The Von Allmen Center for Entrepreneurship
launched a major campaign to establish the
(VACE) conducted its annual CCTS Poster Pitch
Kentucky Children’s Garden, which opened in
Competition. The top winners are:
2011.
Tharunika Venkatesan- 1st
The couple’s daughter, Rani Saha, became
Gaurang Vaidya- 2nd
president of the Saha Foundation in 2020.
Robert Anderson 3rd
Currently, she works in New York City as a
Natalie Jo Hawes - Director’s Award
motion graphics designer and artist alongside
many Fortune 500 companies, post-pro-
Dr Vaidya, pictured below, received second place
duction and design houses, as well as digital
for his research idea on using ultrasound for bed-
agencies.
side fluid status assessment. See the video here:
here: https://internalmedicine.med.uky.edu/im-
Figure above: The Saha Foundation was es- news-1
tablished in 1999 by Dr. Sibu and Becky Saha.
Their daughter, Rani, became president of
the foundation in 2020. The Saha Foundation
promotes research and education of cardiovas-
cular disease. Mark Cornelison | UKPhoto21 | UK Gill Heart & Vascular Institute
MAY
HEART WALK
Thank you! Thank you! Thank you!
Because of your hard work, UK HealthCare raised over $22,000!
Gill Teams Coach Raised
Clotters Jeremy Wood $1,045.16
Pumped-Up Hearts Jacob Stone $5,057.79
UK Cardiovascular ICU Gregory Kempf $51.03
UKHC Gill Heart Institute
Administration Amy Iwahara $3,700.67
UKHC Pharmacy Ashley Schenk $2,337.7621 | Gill Quarterly, Summer 2021
CARDIO-ONCOLOGY
SUBSPECIALTY & SYMPOSIUM
Many cancer therapies may have Medicine Residency at Northeast Cancer and cardiovascular disease
harmful side-effects on the heart Ohio Medical University. Arbune are the top two causes of death in
during or after cancer treatment. completed his Cardiovascular Kentucky and the United States.
Cardio-oncology is dedicated to Disease Fellowship at Case West- Please join us on October 16 for
the early detection and treat- ern Reserve University, where the Inaugural Matthew Szabunio
ment of heart damage from those he served as chief fellow, and an Symposium on Cardio-oncology.
therapies. It also incorporates risk Advanced Cardiovascular Imag- The purpose of the Cardio-oncol-
stratification of patients –partic- ing Fellowship at Yale University ogy. This symposium will provide
ularly those with previous cardiac – New Haven Medical Center in state-of-the art best practice infor-
conditions or other risk factors New Haven, CT. mation regarding the continuum
– prior to undergoing surgery or of cardiac care for the oncology
cardio-toxic chemotherapies or the Arbune has extensive experi- patient. For more details and to
newer immunotherapies. ence in general cardiology, and register see: https://www.cecen-
advanced cardiovascular imag- tral.com/live/20738
For those at risk, cardio-oncology ing. Having clinical and research
teams include both cardiologists experience in cardio-oncology
and oncologists working together at Yale University, he has a keen
to coordinate the best care. This interest in cardiac care for cancer
provider collaboration works to patients. Arbune has participated Who to refer:
protect your heart health while in numerous clinical research • Cardiac patients with diagnosis
also providing the most effective projects and presented at many of cancer.
cancer treatment. national conferences. • Cancer patients with established
cardiotoxicity from cancer thera-
Amit Arbune, MD, MHA, FACC, “I am focused on protecting your pies.
is a cardiologist with a special patients’ hearts from the side • Cancer patients undergoing
interest in cardiac care for cancer effects of cancer treatments and therapies that may affect the heart
patients. Dr. Arbune received his keeping them strong to receive (including radiation).
medical degree from MGM Med- the best available cancer treat- • Cancer survivors (especially
ical College in India. He holds a ments. My team and I provide a childhood survivors).
master’s in healthcare administra- collaborative care plan tailored
tion from the University of Ken- for these patients.” To refer a patient, call 800-888-
tucky and completed his Internal – Amit Arbune, MD, MHA, 5533.JUNE
AORTIC ANEURYSM R35
Thanks to a $5.6 million grant Understanding why the aorta’s Daugherty received a seven-year
from the National Institutes of tissue lends itself to thoracic $5.6 million R35 grant from the
Health (NIH), a University of aortic aneurysms and dissec- NIH’s National Heart, Lung,
Kentucky College of Medicine tion (TAAD) could translate and Blood Institute (NHLBI) to
team will study the culprit into treatments for the dis- study the tissues of the aorta and
behind thoracic aortic aneu- ease, says Alan Daugherty, provide insight into how and
rysms, which could lead to a Ph.D., chair of the UK Depart- why TAAD occurs.
treatment for the potentially ment of Physiology, Gill Foun-
deadly disease. dation Chair in Preventative “We hope this research program
Cardiology, and director of the will contribute to providing new
A thoracic aortic aneurysm is Saha Cardiovascular Research medical options so that watch-
a weakened area in the aorta, Center and the Saha Aortic ing and waiting won’t be the
the main artery that carries Center in the UK College of only option for these patients,”
blood away from the heart to Medicine. Daugherty said. “This grant
the body. The condition puts gives us an opportunity to find
people at risk for a dissection, There are currently no medica- pathways for a drug therapy to
the rupturing of the aorta that tions to directly treat the condi- stop the aneurysm from growing
can cause life-threatening tion or prevent an aneurysm from so patients can avoid surgical
bleeding or sudden death. growing. Patients typically take intervention.”
a “watchful waiting” approach,
where the aneurysm is scanned
regularly to see if it grows enough
to require surgical repair.23 | Gill Quarterly, Summer 2021
While thoracic aortic aneu- “The tissue throughout the As the NHLBI R35 grant is in-
rysms can happen sponta- aorta is apparently similar. tended to give scientists more
neously and without a known If you looked at different freedom to conduct ground-
cause, they are also associated samples under a microscope, breaking research, it will
with a wide range of both ge- you probably wouldn’t see also give Daugherty’s lab the
netic and non-genetic diseases any obvious differences. But flexibility to pursue potential
or syndromes. In these cases, because the locations of aneu- contributions of other tissues
aneurysms tend to occur in rysms associated with diseases and organs to TAAD, as well as
very specific parts of the aorta. are so specific, that may not TAAD’s effects on them.
be the case,” Daugherty said.
“We hope this research pro- “So what is it about this tissue The program will also build
gram will contribute to pro- that makes it quite different upon his lab’s ongoing re-
viding new medical options depending on where it is? And search to expand the under-
so that watching and waiting why is it that certain diseas- standing of how the aorta
won’t be the only option for es affect certain parts of the develops. His team has already
these patients,” Daugherty aorta and leave the rest totally identified unique mechanisms
said. “This grant gives us an untouched?” in the way that the aorta grows
opportunity to find pathways that could provide more in-
for a drug therapy to stop the The key may be in a material sight for potential drug devel-
aneurysm from growing so called extracellular matrix, opment.
patients can avoid surgical which binds aortic tissue to-
intervention.” gether. The extracellular ma- Two other researchers in the
trix is what degrades to weak- Saha Cardiovascular Research
en the tissue in an aneurysm, Center – Xiangan Li and
For example, Daugherty says
and researchers currently have Sidney Whiteheart – recent-
that men in their 60s who have
little understanding about ly received NIH R35 grants.
smoked tend to have an an- Daugherty says it’s significant
what makes that happen.
eurysm in the lower portion that UK has this number of
of the aorta. For people with Using state-of-the-art tools the prestigious awards with-
Marfan syndrome, an inherited including ultrasonography, in the area of cardiovascular
disorder that affects connective MRI and micro-computed research.
tissue, aneurysms commonly tomography, Daugherty’s lab
occur in the section of the aor- will seek to define how the “The R35 is unique in that it
ta that connects to the heart. extracellular matrix fibers are really focuses on the individ-
His research program seeks to laid down and what makes ual and their research track
them either stable or unstable. record rather than the specif-
understand what causes the
Their findings in mouse mod- ics of a project,” Daugherty
differences, and the findings
els will be validated in human said. “These awards recognize
could provide a target for drug a chronic level of achievement
TAAD samples from a tissue
development. and are a testament to the
bank at the Baylor College of
Medicine. strength of cardiovascular re-
search across this campus.”
Adapted from UKNow.24 | UK Gill Heart & Vascular Institute
CV-RPA NEWS
VITAL
Beth Garvy, PhD, and Sidney White- Dr. Garvy and Dr. Whiteheart de- examining COVID-19-associated
heart, PhD, originally planned to scribe their Alliance team’s work as coagulopathies. The core team was
study blood clotting in HIV-positive “building an airplane while it’s still originally composed of basic re-
patients when they first approached flying.” Their team is conducting searchers, including Jeremy Wood,
one another to establish a unified research and clinical trials, and the PhD, division of cardiology, who
research team. Then COVID-19 infrastructure is growing and im- studies coagulation factors and is
emerged, and their focus shifted proving day by day, but there are still working to include more clinical
on the disease that started a global some tasks left to officially establish faculty in their infectious disease
pandemic. a system that works like a well-oiled division who deal with monitoring
machine. Based on their current coagulation therapies. VITAL recent-
Dr. Garvy and Dr. Whiteheart now trajectory, that goal is attainable. ly added Muhammad Gul, MD, and
lead what is called the Virus-In- Brittany Bissell, MD, two new faculty
duced Thrombosis Alliance (VITAL), “Had this infrastructure been there members with experience treating
a team supported by the University from the beginning, we might not COVID-19 patients. The project has
of Kentucky College of Medicine’s have ever had to backtrack,” Dr. the framework to allow for expan-
Alliance Research Initiative that is Garvy said. “But the good thing is sion into studies of other viruses
working to bridge the gap between that we’re now getting to the point such as influenza and hepatitis C,
infectious diseases and cardiovas- where we can bring other people another major disease in Kentucky.
cular diseases, one of the Research on, and we can help them get what
Priority Areas from the UK Office of they need because we have now built Dr. Garvy and Dr. Whiteheart are
the Vice President for Research. Dr. the airplane, and it can fly, and we excited to get wheels back on the
Garvy is associate dean for biomed- are actually getting the workings to ground in Africa after COVID-19
ical education and professor in the be a better resource for the rest of restrictions are lifted. They are also
department of microbiology, im- campus.” hopeful that the “airplane” they have
munology, and molecular genetics, built will be useful for the next round
while Dr. Whiteheart is a professor VITAL began with a search for an- of researchers.
of molecular and cellular biochem- swers on why HIV-positive patients
istry. had an increased risk of blood clots. “I hope that what we have been able
The team has studied populations to build, will be maintained over a
The short game of VITAL is to gen- in Kentucky, and was beginning to prolonged period of time, that this
erate publications and collaborate examine HIV-positive patients in will just be the beginning for our
on grants that fund critical research Durban, South Africa, through a col- junior faculty, for fellows, for the
projects. The long game is a much laboration with the African Health students who are coming in, that
greater goal – establishing a re- Research Institute led by VITAL they’ll be able to use the infrastruc-
search infrastructure that will make team member Zach Porterfield, MD, ture that we’re going to need for that
studying infectious diseases a much PhD, assistant professor of microbi- and build it to a greater degree,” Dr.
smoother, more efficient process ology, immunology, and molecular Whiteheart said. “There’s still more
for clinicians and scientists so when genetics. that needs to be done, but I feel like
new viruses inevitably appear, as In response to the global pandem- it’s moving and it’s growing. And
COVID-19 did, UK will be even more ic, VITAL translated its research to then infectious disease research at
prepared for tackling related issues. COVID-19, which has a different the University of Kentucky will have
immune response than seen in HIV. a great future because of this infra-
The Alliance has developed a project structure.”
Adapted from In the Loop.25 | Gill Quarterly, Summer 2021
RESEARCH FEATURE
PRORENIN RECEPTOR
The Prorenin Receptor and its Soluble Form Contrib- What they found: The deletion of PRR in liver
ute to Lipid Homeostasis. Eva Gatineau, Gertrude induced hepatomegaly, hypercholesterolemia, liver
Arthur, Audrey Poupeau, Kellea Nichols, Brett T. inflammation and injury, and disrupted hepatic lipid
Spear, Nathan R. Shelman, Gregory Graf, Ryan homeostasis causing an increase in hepatic cholester-
Temel, Frédérique Yiannikouris. Am J Physiol ol and a decrease in hepatic triglycerides contents. In
Endocrinol Metab. 2021 Mar 1;320(3):E609-E618. addition, the deletion of hepatic PRR lowered hepatic
doi: 10.1152/ajpendo.00135.2020. https://pubmed. LDLR and SORT1 proteins but stimulated hepat-
ncbi.nlm.nih.gov/33459178/ ic cholesterol synthesis (up-regulation of hepatic
SREBP2 and HMG CoA-R genes) suggesting that he-
Obesity is associated with several deleterious chang- patocyte sensed a shortage in cholesterol uptake and,
es in lipid metabolism and alterations in hepatic to compensate, increased cholesterol synthesis. The
lipid metabolism. Hyperlipidemia is a risk factor for measurement of total sPRR contents in fat indicated
cardiovascular disease and is estimated to be respon- that the increase in circulating sPRR, observed in Liv-
sible for more than half of cardiovascular mortality. er PRR KO mice, originated from the adipose tissue.
We previously identified the prorenin receptor (PRR) Mechanistic studies performed in vitro indicated that
as a potential contributor to liver steatosis. PRR contributed to triglycerides homeostasis through
a PRR-PPARγ dependent mechanism whereas both
What they did: In this study, we investigated the PRR and sPRR contributed to hepatic cholesterol
contribution of PRR and its soluble form, sPRR, homeostasis.
to lipid homeostasis. PRR-floxed male mice were
treated with an adeno-associated virus with thyrox- Why it matters: The remarkable phenotype demon-
ine-binding globulin promoter driven Cre to delete strated the importance of liver PRR and sPRR in
PRR in the liver (Liver PRR KO mice). lipid homeostasis and highlighted a new paradigm of
crosstalk between the liver and the adipose tissue.
Visit : https://www.research.uky.edu/research-priorities-initiative-cardio-
vascular-diseases/cardiovascular-diseases for more information.
Please visit: https://redcap.uky.edu/redcap/surveys/?s=W4WY8DEHEH
to join the CV-RPA.Ahmed Abdel-Latif Length-Dependent Activation in Lisa Cassis
Lysophosphatidic Acid Mediates Human Myocardium Center of Research in Obesity and
Cardiac Inflammation After Acute National Heart Lung and Blood Cardiovascular Disease COBRE
Infarction Institute Core A: Admin
National Heart Lung and Blood 09/15/20- 07/31/24 Core National Institute of General
Institute Medical Sciences
08/01/17-07/31/22 Dual Filament Control of Myocar- 09/08/08-07/31/23
dial Power and Hemodynamics
Doug Andres University of Missouri Supplemental Environmental Proj-
RIT1-Mediated Protection Fol- 08/25/20- 07/31/24 ect Compliance Assistance Tools
lowing Traumatic Brain Injury and Services
National Institute of Neurological Computer Modeling of Myosin KY Department of Environmental
Disorders & Stroke Binding Protein C and its Effect Protection
02/15/2018-01/31/23 on Cardiac Contraction 07/01/07-12/31/21
Case Western Reserve
RIT1 as Novel Driver Oncogene in 04/01/19-03/31/23 EPSCoR Administrative
Lung Adenocarcinoma KY Economic Development Cab
KY Lung Cancer Research Fund Thick-Filament Regulation In 02/01/19-06/30/22
07/01/16-06/30/21 Human Heart Failure
Washington State University Healthy Kentucky Research Build-
An Innovative Therapeutic Ap- 07/01/19-06/30/22 ing Fit-up for Vascular Research
proach to Treat Cardiomyopathy Office of the Director
Army Medical Research and Ma- CRCNS: Multi-Scale Models of 09/23/19-10/31/21
teriel Command Proprioceptive Encoding for Sen-
07/01/20-06/30/23 sorimotor Control Sex Differences in Angiotensin-In-
Emory University duced Vascular Diseases
Ken Campbell 09/16/16-05/31/2022 National Heart Lung and Blood
Multiscale Modeling of Inherited Institute
Cardiomyopathies and Therapeu- Awards for members of Gill Heart 03/21/12-05/31/22
tic Interventions & Vascular Institute total over
National Heart Lung and Blood $33 Mil per year!
Institute
08/03/17-07/31/2227 | Gill Quarterly, Summer 2021
Alan Daugherty Toward Early Diagnosis of Long QT Scott Gordon
University of Kentucky- Baylor Syndrome Using Machine Learning The Role of High Density Lipopro-
College of Medicine Aortopathy Re- and Molecular Dynamics Simulation tein Associated Protease Inhibitor
search Center of KCNH2 Activity in Protection Against Ath-
American Heart Association Loyola University erosclerosis.
04/01/18-03/31/22 01/01/21- 12/31/21 National Heart Lung and Blood
Institute
JMJD3 Regulates Abdominal Aortic Florin Despa 08/20/18-07/31/21
Aneurysm Expansion The Amylin Dyshomeostasis Hy-
University of Michigan pothesis of Vascular Contributions to Protease Activity in Atherosclerotic
04/01/21-06/30/21 Cognitive Impairment and Dementia Plaque Formation and Protection
(VCID) by Novel HDL-targeting Protease
A Mechanistic Study to Elucidate National Institute of Neurological Inhibitors
the Role of Protein S in Elevating Disorders & Stroke Medical Foundation
the Risk of Thrombosis in Obese, 04/01/20-03/31/25 12/01/18-11/30/21
Pre-menopausal Women
Louisiana State University Health Role of Systemic Amylin Dysho- Gregory Graf
Sciences Center- New Orleans meostasis in Alzheimer’s Disease Contributions of hepatic and
01/15/21- 12/31/24 National Institute on Aging intestinal pathways to cholesterol
09/15/16- 05/31/21 excretion
Determinants of Aorta Heterogene- National Institute Diabetes &
ity Ming Gong Digestive & Kidney
National Heart Lung and Blood Targeting Timing of Food Intake 09/13/17-07/31/22
Institute as a Novel Strategy against Disrup-
06/01/21-05/31/28 tion of Blood Pressure Circadian The Don S. Fredrickson Lipid
Rhythm in Diabetes Research Conference
Macrophage Migration Inhibitory National Heart Lung and Blood National Heart Lung and Blood
Factor and Urinary Pain Institute Institute
Lexington Biomedical Research 01/15/19-10/31/22 09/01/20-08/31/21
Institute
07/01/19-06/30/23 A Novel Mechanism by which Brian Jackson
Smooth Muscle BMAL1 Regulates Graduate Research Fellowship Pro-
Brian Delisle IL-6 and Sexual Dimorphism of gram
Transcriptional Regulation of Abdominal National Science Foundation
KCNH2 Aortic Aneurysm 08/01/18-07/31/23
National Heart Lung and Blood National Heart Lung and Blood
Institute Institute Jing Li
03/08/19-02/28/23 08/20/18-07/31/22 Project MISSION: Developing a mul-
ticomponent, Multilevel Implemen-
Circadian Clock Regulation of Myo- tation Strategy for Syncope OptImal-
cardial Ion Channel Expression and Internal Medicine is currently the Care thrOugh eNgagement
Function highest funded division in the Col- National Heart Lung and Blood
University of Florida lege of Medicine. . Institute
09/01/20- 05/31/21 08/01/2017-07/31/2128 | UK Gill Heart & Vascular Institute
RESEARCH FUNDING
CONTINUED
Xiangan Li Fat Nerve Recording in Mice Gia Mudd-Martin
Relative Adrenal Insufficiency is a American Physiological Society Corazón de la Familia (Heart of the
Risk Factor and an Endotype for 10/01/19-07/31/21 Family)
Sepsis National Institute of Nursing Re-
National Institute of General Medical Hong Lu search
Sciences Atherosclerosis Mechanisms: Angio- 03/02/17-01/31/22
05/01/21- 04/30/26 tensin II Production and Action
National Heart Lung and Blood Heart of the Family: A Cardiovas-
Mechanism of Adrenal Insufficiency Institute cular Disease and Type 2 Diabetes
as A Risk Factor for Sepsis 05/01/18-03/31/22 Risk Reduction Intervention in
National Institute of General Medical High-Risk Rural Families
Sciences Andrew Morris National Institute of Nursing Re-
09/01/17-08/31/21 Define the Twist-ATX-LPAR1 search
Signaling Axis in Promoting Obe- 09/07/20- 06/30/25
Synthetic HDL a Potential Sepsis sity-Associated Triple Negative
Therapy Breast Timothy Mullett
National Institute of General Medical Cancer Army Medical Research and Using Biomarkers and Imaging in
Sciences Materiel Command Fungal Regions to Improve Lung
11/01/15-11/30/21 04/15/16-04/14/21 Cancer
Diagnosis Vanderbilt University
Zhenyu Li Anniston Community Health Sur- 04/01/19-03/31/22
Inflammasome Activation Triggers vey: Follow-up Study and Dioxin
Systemic Coagulation in Sepsis Analyses Kentucky Lung Cancer Survivorship
National Heart Lung and Blood National Cancer Institute Program
Institute 05/01/19-04/30/21 Bristol Myers Squibb Foundation
05/15/19-04/30/23
Incorporated
Debra Moser 09/01/14- 12/31/21
A Novel Mechanism of Immuno- Rural Intervention for Caregivers’
suppression in Sepsis: Depletion of Heart Health (RICHH) Mariana Nikolova-Karakashian
Monocytes and Macrophages National Institute of Nursing Re- Ceramide and Acute Phase Proteins
National Institute of General Medi- search Elevation During Aging
cal Sciences 09/26/16-06/30/21 National Institute on Aging
09/20/19-06/30/23
08/01/02-05/31/23
Online Cognitive Behavioral
Heart-Platelet Crosstalk: JNK, AFib, Therapy for Depressive Symptoms Jonathan Satin
and Thrombogenesis in Rural Coronary Heart Disease Monomeric G-Proteins and Cardio-
Rush University Medical Center Patients protection from Heart Failure
05/15/19-02/28/23 Patient Centered Outcomes Re- National Heart Lung and Blood
search Institute Institute
Analia Loria 10/01/2020 to 09/30/2024 09/01/17- 08/31/21
Effect of Early Life Stress on Obesi-
ty-Induced Hypertension in Mice
National Heart Lung and Blood
Institute
12/01/17-11/30/2229 | Gill Quarterly, Summer 2021
RESEARCH FUNDING
CONTINUED
An Innovative Therapeutic Approach Therapeutic Targeting of Metabolic Regulation and Function of IL33
to Treat Cardiomyopathy microRNAs as a New Treatment During Neonatal RSV Infection
Army Medical Research and Materiel Paradigm for NASH Louisiana
Command Aalborg University State University
07/01/20- 6/30/23 01/01/19-12/31/24 05/05/18-07/31/21
Nancy Schoenberg Dongfang Wang Nancy Webb
Community to Clinic Navigation to Development of a Paracorporeal Serum Amyloid A, Inflammasome
Improve Diabetes Outcomes Pump-Integrated Artificial Lung for Activation, and Abdominal Aortic
National Institute Diabetes & Diges- Transport of Warfighters with Acute Aneurysms
tive & Kidney Respiratory Distress Syndrome National Heart Lung and Blood
08/01/17-07/31/22 (ARDS) Institute
Army Medical Research and Materiel 01/01/17-12/31/21
Implementing an Evidence-Based Command
mHealth Diet and Activity Interven- 08/15/19 -08/14/22 NRSA T32: Pharmacology and Nu-
tion: Make Better Choices 2 for Rural tritional Sciences:
Appalachians SBIR: Development of a TransApical National Institute Diabetes & Diges-
National Heart Lung and Blood to Aorta Double Lumen Cannula for tive & Kidney
Institute a Neonate LVAD 08/15/00-07/31/21
08/01/20- 04/30/25 W-Z Biotech LLC
04/01/19-07/31/21 Jonathan Wenk
Venkateswaran Subramanian Force Validated Heart Valve Surgical
Calpains and Abdominal Aortic Shuxia Wang Planning Tool
Aneurysms Thrombospondin 1 in obesity associ- University of Arkansas
National Heart Lung and Blood ated inflammation and insulin resis- 09/01/19-08/31/22
Institute tance National Institute Diabetes
08/10/17-07/31/21 & Digestive & Kidney Sidney Whiteheart
08/20/17-05/31/21 Platelet Exocytosis and Endocytosis
Ryan Temel in Thrombosis and Immunity
TRAF6 Nanoimmunotherapy to Christopher Mark Waters National Heart Lung and Blood
Resolve Plaque Inflammation Biophysical Mechanisms of Hyper- Institute
Mount Sinai oxia-Induced Lung injury 04/01/20-03/31/28
08/15/18-06/30/21 National Heart Lung and Blood
Institute Regulatory Mechanisms of Glycopro-
Targeting MicroRNA-33 To Reduce 04/15/20- 03/31/24 tein Sialylation
Intracranial Atherosclerosis and Case Western Reserve
Other Neurovascular Hallmarks of ASK1 and Ventilator-Induced Lung 01/01/21- 11/30/24
Vascular Cognitive Impairment and Injury
Dementia National Heart Lung and Blood Jeremy Wood
National Institute of Neurological Institute Protein S Anticoagulant Activity:
Disorders & Stroke 12/15/16-11/30/21 Biochemical Mechanisms and Struc-
04/01/19-03/31/21 tural Studies National Heart Lung
and Blood Institute
09/15/15-03/31/2130 | UK Gill Heart & Vascular Institute SEMINARS AND JOURNAL CLUBS * Please note if these seminars are still occurring, they will be online only. Check website for details. Cardiovascular Seminar Series Fridays at 8:00 am This forum brings to campus prominent external speakers and provides presentations by UK faculty to ensure their research expertise is widely known. https://cvrc.med.uky.edu/cvrc-current-seminar-schedule Cardiovascular Journal Club Tuesdays at 8:00 am Presenters in this forum discuss specific citations including basis for this publication's selection, strengths and weaknesses, from the perspective as if he/she were the original reviewer. For more information contact: Greg Graf, Ph.D. or Ryan Temel, Ph.D. https://cvrc.med.uky.edu/cvrc-current-journal-club-schedule Blood Cell Journal Club 4th Friday of each month at 4:00 pm The journal club was started a number of years ago in an effort to provide a focal point for the hemostasis community at UK. The focus is usually on platelets but they also discuss papers on Coagulation and Immune responses. https://cvrc.med.uky.edu/cvrc-blood-cell-journal-club-2018
31 | Gill Quarterly, Summer 2021
PUBLICATIONS
APRIL-JUNE
Ai AL, Smyth SS. Depression After Arthur G, Osborn JL, Yiannikouris Beavers CJ, Effoe SA, Dobesh PP.
Open Heart Surgery: Influences of FB. (Pro)renin receptor in the kid- Selatogrel: A Novel Subcutaneous
Optimism, Sex, and Event-Related ney: function and significance. Am J P2Y12 Inhibitor. J Cardiovasc Phar-
Medical Factors. J Nerv Ment Dis. Physiol Regul Integr Comp Physiol. macol. 2021 Jun 8. doi: 10.1097/
2021 Mar 1;209(3):212-217. doi: 2021 Apr 1;320(4):R377-R383. doi: FJC.0000000000001079.
10.1097/NMD.0000000000001285. 10.1152/ajpregu.00259.2020.
Beavers CJ, Jennings DL. Use of
Ahmed T, Grigorian AY, Messerli Aru RG, Tyagi SC, Minion DJ, Glycoprotein IIb/IIIa Inhibitors
AW. Management of Acute Coro- Orr NT, Bounds MC. Carotid-Ca- in the Modern Era of Acute Cor-
nary Syndrome in Patients with Liver rotid Transposition for Zone 1 Tho- onary Syndrome Management:
Cirrhosis. Am J Cardiovasc Drugs. racic Endovascular Aortic Repair. A Survey of Cardiovascular Clin-
2021 May 29. doi: 10.1007/s40256- Ann Vasc Surg. 2021 May 2:S0890- ical Pharmacists. J Pharm Pract.
021-00478-6. 5096(21)00376-9. doi: 10.1016/j. 2021 Jun;34(3):372-377. doi:
avsg.2021.04.025. 10.1177/0897190019872386.
Ahmed T, Lodhi SH, Anstead MI,
Messerli AW. Cerebral paradox- Backer CL. Regionalization Equals Browder KL, Ather A, Pandya KA.
ical embolisation in a patient with Excellence in Pediatric Tracheal Sur- The effects of propofol on extracor-
cystic fibrosis with patent foramen gery. Ann Thorac Surg. 2021 May poreal membrane oxygenation oxy-
ovale: a comparative review of 20:S0003-4975(21)00867-5. doi: genator exchange. Int J Artif Organs.
literature. BMJ Case Rep. 2021 May 10.1016/j.athoracsur.2021.04.087. 2021 May 13:3913988211016007.
24;14(5):e242302. doi: 10.1136/bcr- doi: 10.1177/03913988211016007.
2021-242302. Ballout JA, Ahmed T, Kolodziej
AR. COVID-19 and Heart Trans- Chanzu H, Lykins J, Wigna-Kumar
Ahn S, Esquivel JH, Davis EM, Lo- plant: A Case Series and Review of S, Joshi S, Pokrovskaya I, Storrie
gan JG, Chung ML. Cardiovascular the Literature. Transplant Proc. B, Pejler G, Wood JP, White-
Disease Incidence and Risk in Family 2021 Feb 25:S0041-1345(21)00137- heart SW. Platelet α-granule cargo
Caregivers of Adults With Chronic 8. doi: 10.1016/j.transpro- packaging and release are affected
Conditions: A Systematic Review. J ceed.2021.02.015. by the luminal proteoglycan, ser-
Cardiovasc Nurs. 2021 Apr 30. doi: glycin. J Thromb Haemost. 2021
10.1097/JCN.0000000000000816. Baroumand AG, Arbune AA, Apr;19(4):1082-1095. doi: 10.1111/
Strobbe G, Keereman V, Pinborg LH, jth.15243.
AlSiraj Y, Thatcher SE, Liang CL, Fabricius M, Rubboli G, et al. Auto-
Ali H, Ensor M, Cassis LA. Thera- mated ictal EEG source imaging: A Clouser JM, Sirrine M, McMullen
peutic Assessment of Combination retrospective, blinded clinical valida- CA, Cowley AM, Smyth SS, Gupta
Therapy with a Neprilysin Inhibitor tion study. Clin Neurophysiol. 2021 V, Williams MV, Li J. “Passing Out
and Angiotensin Type 1 Receptor Apr 27:S1388-2457(21)00530-7. doi: is a Serious Thing”: Patient Expec-
Antagonist on Angiotensin II-In- 10.1016/j.clinph.2021.03.040. tations for Syncope Evaluation and
duced Atherosclerosis, Abdominal Management. Patient Prefer Adher-
Aortic Aneurysms, and Hyperten- Bazan VM, Taylor EM, Gunn TM, ence. 2021 Jun 4;15:1213-1223. doi:
sion. J Pharmacol Exp Ther. 2021 Zwischenberger JB. Overview 10.2147/PPA.S307186.
Jun;377(3):326-335. doi: 10.1124/ of the bicaval dual lumen cannula.
jpet.121.000525. Indian J Thorac Cardiovasc Surg.
2021 Apr;37(Suppl 2):232-240. doi:
10.1007/s12055-020-00932-1.You can also read
